Recently, Eli Lilly (SYM: LLY) surged more than 14% following positive news about its promising GLP-1 obesity treatment. The move came after the pharmaceutical giant announced that its oral GLP-1 receptor agonist, orforglipron, successfully met the primary endpoint in a Phase 3 clinical trial targeting adults with type 2 diabetes.
According to Seeking Alpha, “Citing topline data from its ACHIEVE-1 clinical trial for a key secondary endpoint, the Indiana-based pharma giant said that the once-daily pill reduced weight by ~8% on average (16.0 lbs) at the highest dose in the 40-week trial.”
This is a major development not just for Eli Lilly, but for the entire obesity treatment space — a sector that continues to gain traction among both healthcare providers and investors.
The news also triggered rallies in several smaller-cap biotech names that are developing similar treatments. These companies are aggressively advancing novel obesity drug candidates that could potentially carve out a meaningful share of what’s projected to be a $100 billion-plus market.
Let’s take a deeper dive into each of these names — and why now could be a smart time to pay attention.
|
Company: Viking Therapeutics (SYM: VKTX) Oversold and under-the-radar — with major upside potential Biotech investors have been keeping a close eye on Viking Therapeutics, and for good reason. While shares saw a dip following a recent secondary offering, the fundamentals remain compelling, especially given the company’s potential in the booming obesity market. At present, the global market for obesity treatment drugs is valued at around $12.8 billion. But according to analysts at Research and Markets, that number could skyrocket to $105 billion by 2035. That’s an enormous growth trajectory — and Viking is well-positioned to benefit. Its most promising asset is VK2735, a dual GLP-1/GIP receptor agonist currently being tested in both subcutaneous and oral forms. The subcutaneous version of VK2735 has already demonstrated impressive weight loss results in Phase 2 trials — with participants losing up to 14.7% of their body weight over 13 weeks. Even the oral version has shown encouraging results, with weight loss of up to 8.2% in just 28 days. That kind of efficacy puts VK2735 in close competition with some of the more advanced treatments from major players like Eli Lilly and Novo Nordisk. CEO Brian Lian has confirmed that a Phase 3 trial for the subcutaneous version is expected to begin in the second quarter of 2025. He also hinted at an upcoming Phase 2 trial for the oral version, which could open up an even larger market, considering the demand for non-injectable options. With significant catalysts on the horizon and a product that is showing real promise, Viking is a biotech to watch closely. |
Mode Mobile
Market’s down 10% YTD – Buffett’s Berkshire up 13%
Markets swing. Emotions flare. But Warren Buffett doesn’t flinch—because his money works even while he sleeps. His rule is simple: “If you don’t make money while you sleep, you will work until you die.”
And a new player in the smartphone industry is putting his philosophy into practice. Their vision of passive income for screen time has driven 32,481% growth and brought in over $75M in revenue.
Mode Mobile’s EarnPhone is flipping the smartphone industry on its head, and you can still invest in their pre-IPO offering at $0.26/share before May 1st.
⚠️ Act Now – Nasdaq ticker MODE secured and price set to move on May 1st.
|
Company: Structure Therapeutics (SYM: GPCR) Tapping into a new mechanism for weight loss Structure Therapeutics is another name benefiting from the recent surge in investor interest around obesity drug development. While still at an earlier stage than Viking, the company has some intriguing potential thanks to its novel drug design approach. In late 2024, Structure announced the selection of its lead obesity candidate, ACCG-2671 — a first-in-class, oral small molecule DACRA (Dual Amylin and Calcitonin Receptor Agonist). This compound targets weight loss through a different biological pathway than traditional GLP-1 agonists, which could help differentiate it in a competitive market. According to the company’s press release, ACCG-2671 is expected to enter Phase 1 clinical development by the end of 2025. While that’s still a long runway, analysts already estimate potential worldwide sales of $6.3 billion by 2040, assuming the candidate successfully progresses through trials. Structure’s advantage lies in its oral formulation — a factor that many patients prefer over injectables — and its differentiated mechanism of action. If the drug proves safe and effective in clinical studies, it could become a valuable asset for the company, or even make Structure an attractive acquisition target. Given its early stage, the stock is speculative, but with a unique value proposition and the right market conditions, it offers a compelling long-term opportunity. |
Investors Alley
In a Collapse, Cash Is Everything
When the global system starts to fail — when tariffs trigger retaliation and Wall Street panics — only one thing matters:
Cash in your hand.
Not stock projections. Not analyst opinions. Not “the market recovering someday.”
The only thing that helps you pay bills, fund your retirement, or sleep at night… is income you can count on right now.
That’s why I built the Monthly Dividend Paycheck Calendar.
It’s a simple, powerful strategy that’s helping investors collect 11–22 paychecks a month, even as China guts the global economy and Wall Street scrambles for answers.
|
Company: Altimmune (SYM: ALT) A late-stage contender with impressive Phase 2 data Last but not least, Altimmune is developing one of the most promising obesity drug candidates outside of the big pharma names: pemvidutide. In Phase 2 trials, pemvidutide produced a mean weight loss of 15.6% in patients on the 2.4 mg dose — with more than 30% of participants achieving at least 20% weight loss. Those are very competitive results that place it squarely in the conversation with leaders like Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy. But it’s not just about weight loss. Pemvidutide also appears to improve key cardiovascular and metabolic risk factors:
This is particularly important because obesity is often linked with comorbidities like hypertension and dyslipidemia. A treatment that addresses both weight and related health risks could be highly sought-after. Altimmune recently reached an agreement with the FDA on efficacy and safety measures for Phase 3 trials, setting the stage for late-stage development. With a clear regulatory path and strong Phase 2 data, the company could generate substantial investor interest in the months ahead. |
Stocks to Trade
New Algorithm Targets 2X Trades EVERY Monday Morning
20-year trading veteran Tim Bohen has just released a brand-new trading algorithm that targets explosive stock moves every Monday morning. It recently identified SEVEN triple-digit winners in ONE MONTH – go here to get in front of this Monday’s setup now.
